EWA
GYRE icon

EverSource Wealth Advisors’s Gyre Therapeutics GYRE Stock Holding History

EverSource Wealth Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21 Buy
+3
New +$23 ﹤0.01% 4356
2025
Q2 		– Sell
-22
Closed -$170 – 4294
2025
Q1 		$170 Buy
+22
New +$241 ﹤0.01% 3730

Other funds holding GYRE

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EverSource Wealth Advisors's GYRE Position: Q1 2026 in Review

EverSource Wealth Advisors opened a new position in Gyre Therapeutics (GYRE) in Q1 2026: 3 shares worth $21. The stake represents ﹤0.01% of the portfolio and ranks #4356 among its holdings. This is a return to the name: EverSource Wealth Advisors previously reported a position in GYRE as recently as Q1 2025.

EverSource Wealth Advisors first reported a position in GYRE in Q1 2025 and has held it in 2 quarters since. The position peaked at $170 in Q1 2025. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.

  • EverSource Wealth Advisors held 3 shares of Gyre Therapeutics worth $21 as of Q1 2026.
  • Gyre Therapeutics was a new EverSource Wealth Advisors position in Q1 2026.
  • Gyre Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4356 holding.
  • EverSource Wealth Advisors first reported a position in Gyre Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • EverSource Wealth Advisors's Gyre Therapeutics position peaked at $170 in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.